Open AccessKey Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion
Author(s) -
Maki Robert G.,
Blay JeanYves,
Demetri George D.,
Fletcher Jonathan A.,
Joensuu Heikki,
MartínBroto Javier,
Nishida Toshirou,
Reichardt Peter,
Schöffski Patrick,
Trent Jonathan C.
Publication year - 2015
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2014-0471
Subject(s) - gist , medicine , imatinib , imatinib mesylate , chronic myelogenous leukemia , stromal tumor , tyrosine kinase inhibitor , cancer , sunitinib , stromal cell , tyrosine kinase , sarcoma , cancer research , leukemia , pathology , myeloid leukemia , receptor
After the revelation of kinase targeting with orally available small molecules, the use of imatinib in chronic myelogenous leukemia and in gastrointestinal stromal tumor (GIST) has now become commonplace and just two of many examples of the use of kinase inhibitors in cancer. In this article, we discuss important practice points that may impact upon questions of therapy of primary and metastatic GIST, with the hope that the questions addressed in this rare solid tumor can serve as examples of what can be achieved with kinase‐directed therapies in other cancers. We present cases that highlight some of the key issues in GIST management and afterward discuss both points of consensus and controversial issues in what is now recognized as one of the most common forms of sarcoma. Implications for Practice: The treatment of gastrointestinal stromal tumor (GIST) has become sophisticated with the availability of three approved agents in many countries and 15 years of experience with primary and metastatic disease. Important lessons from tyrosine‐kinase inhibitors in GIST can be gleaned from this experience and will impact implementation of similar agents for other cancers.